However, unchanged PFN1 mRNA and protein levels in LCLs of ALS patients and pre-clinical carriers of the PFN1 T109M mutation argue against haploinsufficiency as the pathogenic mechanism. This evidence concerns the gene PFN1 and amyotrophic lateral sclerosis.